ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dolutegravir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2013-11-01

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Cottrell ML, Hadzic T, Kashuba AD.

Clin Pharmacokinet · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1007/s40262-013-0093-2

Bibliografisk träff 2013-11-01

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D.

AIDS · research support, non-u.s. gov't; journal article · DOI 10.1097/qad.0000000000000016

Bibliografisk träff 2013-10-06

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.

Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, Wajima T, Peppercorn AF, Piscitelli SC.

Eur J Clin Pharmacol · controlled clinical trial; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00228-013-1590-9

Bibliografisk träff 2013-09-25

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, extended SPRING-2 Study Group.

Lancet Infect Dis · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(13)70257-3

Bibliografisk träff 2013-09-01

Dolutegravir: first global approval.

Ballantyne AD, Perry CM.

Drugs · review; journal article · DOI 10.1007/s40265-013-0121-4

Bibliografisk träff 2013-07-11

Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).

Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R, Fuji M, Tanimoto N, Jeffrey J, Foster SA, Yoshinaga T, Seki T, Kobayashi M, Sato A, Johnson MN, Garvey EP, Fujiwara T.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm400645w

Bibliografisk träff 2013-07-03

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, extended SAILING Study Team.

Lancet · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(13)61221-0

Bibliografisk träff 2013-07-01

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S, SPRING-1 Team.

AIDS · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1097/qad.0b013e3283612419

Bibliografisk träff 2013-07-01

Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.

Song IH, Borland J, Chen S, Savina P, Peppercorn AF, Piscitelli S.

Antimicrob Agents Chemother · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00728-13

Bibliografisk träff 2013-06-24

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkt220

Bibliografisk träff 2013-05-13

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1128/aac.00292-13

Bibliografisk träff 2013-04-01

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli SC.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2012.04440.x

Bibliografisk träff 2013-03-01

Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa.

Bessong PO, Nwobegahay J.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms14035013

Bibliografisk träff 2013-02-22

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.

Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA.

Retrovirology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1742-4690-10-22

Bibliografisk träff 2013-02-07

Potential benefit of dolutegravir once daily: efficacy and safety.

Fantauzzi A, Turriziani O, Mezzaroma I.

HIV AIDS (Auckl) · research-article; journal article · DOI 10.2147/hiv.s27765

Bibliografisk träff 2013-02-01

[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].

Wajima T, Koshiba T, Ohno K, Nishimura Y, Kobayashi H, Yoshida N, Nagashima M, Fujiwara T.

Jpn J Antibiot · clinical trial, phase i; journal article · DOI 10.1038/ja.2012.104

Bibliografisk träff 2013-01-08

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group.

Lancet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(12)61853-4

Bibliografisk träff 2013-01-07

Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).

Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M, Nichols G.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01791-12

Bibliografisk träff 2013-01-01

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C.

J Acquir Immune Defic Syndr · research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0b013e318276cda9

Bibliografisk träff 2013-01-01

HIV integrase inhibitors: 20-year landmark and challenges.

Métifiot M, Marchand C, Pommier Y.

Adv Pharmacol · research-article; review; journal article · DOI 10.1016/b978-0-12-405880-4.00003-2

Bibliografisk träff 2012-12-07

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, VIKING Study Group.

J Infect Dis · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/infdis/jis750

Bibliografisk träff 2012-11-06

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.112.048918

Bibliografisk träff 2012-11-01

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T.

J Acquir Immune Defic Syndr · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0b013e31826bfd02

Bibliografisk träff 2011-12-28

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA.

J Virol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/jvi.06591-11

Bibliografisk träff 2011-10-20

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S.

Lancet Infect Dis · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(11)70290-0